Company intelligence / Profile preview

MRS Allergy Solutions

Phoenix, Arizona, United States

Ownership: Private
Development stage: Other

Overview

MRS Allergy Solutions operates a commercial allergy testing and immunotherapy program. The company's point-of-care testing evaluates up to 80 cross-reactive allergens simultaneously with results in 15 minutes. Treatment options include sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT). Studies have demonstrated sublingual drops are as effective as injections for allergy relief, with potential to reverse allergic asthma long-term. Most patients experience significant improvement within three months, with relief lasting 10-15 years or longer.

Therapeutic areas: Immunology
Modalities: Allergen extract immunotherapyPoint-of-care diagnostic testing
Industry: Non-Academic Healthcare

Partnerships

Partner pharmacy for immunotherapy dropsMcKesson (medical supply distribution)

Beyond the preview

Go deeper on MRS Allergy Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRS Allergy Solutions.

Explore the full profile